Diamedica Therapeutics Stock Current Asset
| DMAC Stock | USD 2.45 0.03 1.24% |
DiaMedica Therapeutics fundamentals help investors to digest information that contributes to DiaMedica Therapeutics' financial success or failures. It also enables traders to predict the movement of DiaMedica Stock. The fundamental analysis module provides a way to measure DiaMedica Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DiaMedica Therapeutics stock.
At present, DiaMedica Therapeutics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 431.6 K, whereas Net Current Asset Value is projected to grow to (1.4 M). DiaMedica | Current Asset |
DiaMedica Therapeutics Company Current Asset Analysis
DiaMedica Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current DiaMedica Therapeutics Current Asset | 5.24 M |
Most of DiaMedica Therapeutics' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DiaMedica Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
DiaMedica Current Asset Historical Pattern
Today, most investors in DiaMedica Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various DiaMedica Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of DiaMedica Therapeutics current asset as a starting point in their analysis.
DiaMedica Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
DiaMedica Total Assets
Total Assets |
|
In accordance with the recently published financial statements, DiaMedica Therapeutics has a Current Asset of 5.24 M. This is 99.76% lower than that of the Biotechnology sector and 99.51% lower than that of the Health Care industry. The current asset for all United States stocks is 99.94% higher than that of the company.
DiaMedica Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DiaMedica Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DiaMedica Therapeutics could also be used in its relative valuation, which is a method of valuing DiaMedica Therapeutics by comparing valuation metrics of similar companies.DiaMedica Therapeutics is currently under evaluation in current asset category among related companies.
DiaMedica Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of DiaMedica Therapeutics from analyzing DiaMedica Therapeutics' financial statements. These drivers represent accounts that assess DiaMedica Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of DiaMedica Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 58.1M | 159.0M | 77.5M | 41.8M | 92.5M | 97.1M | |
| Enterprise Value | 54.4M | 151.7M | 72.8M | 37.5M | 88.3M | 92.8M |
DiaMedica Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 39.36 M | ||||
| Shares Outstanding | 37.96 M | ||||
| Shares Owned By Insiders | 26.65 % | ||||
| Shares Owned By Institutions | 22.01 % | ||||
| Number Of Shares Shorted | 202.17 K | ||||
| Price To Earning | (3.52) X | ||||
| Price To Book | 1.80 X | ||||
| EBITDA | (21.24 M) | ||||
| Net Income | (19.38 M) | ||||
| Cash And Equivalents | 38.44 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 400 K | ||||
| Current Ratio | 25.50 X | ||||
| Book Value Per Share | 1.34 X | ||||
| Cash Flow From Operations | (18.73 M) | ||||
| Short Ratio | 4.75 X | ||||
| Earnings Per Share | (0.60) X | ||||
| Price To Earnings To Growth | (0.07) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 1.74 | ||||
| Market Capitalization | 91.86 M | ||||
| Total Asset | 54.16 M | ||||
| Retained Earnings | (115.56 M) | ||||
| Working Capital | 50.89 M | ||||
| Current Asset | 5.24 M | ||||
| Current Liabilities | 1.05 M | ||||
| Net Asset | 54.16 M |
About DiaMedica Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DiaMedica Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DiaMedica Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DiaMedica Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with DiaMedica Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DiaMedica Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaMedica Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against DiaMedica Stock
| 0.72 | ELYM | Eliem Therapeutics | PairCorr |
| 0.61 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.57 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.45 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to DiaMedica Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DiaMedica Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DiaMedica Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DiaMedica Therapeutics to buy it.
The correlation of DiaMedica Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DiaMedica Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DiaMedica Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DiaMedica Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out DiaMedica Therapeutics Piotroski F Score and DiaMedica Therapeutics Altman Z Score analysis. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.Note that the DiaMedica Therapeutics information on this page should be used as a complementary analysis to other DiaMedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is DiaMedica Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Return On Assets (0.30) | Return On Equity (0.47) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.